Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951221 · ClinicalTrials.gov registry record · Phase 1
New Formulation and Food Effect Study of BIIB074
A Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02951221: Completed Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, sponsored by Biogen.
NCT02951221 is a Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain that has completed, run by Biogen. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02951221, a Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of the study are to assess the relative bioavailability of the BIIB074 direct compression formulation (DCF) to the BIIB074 roller compaction formulation (RCF) and to determine the effect of a high-fat meal on the pharmacokinetics (PK) of the BIIB074 DCF. The secondary objective of the study is to assess the safety and tolerability of BIIB074 administered as the DCF following single oral dose administration in healthy participants.
Conditions Studied
Interventions
- DRUG BIIB074 Treatment A
- DRUG BIIB074 Treatment B
- DRUG BIIB074 Treatment C
- DRUG BIIB074 Treatment D
Study Locations (1)
Florida
- Research Site - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
What the finished NCT02951221 record still lists
NCT02951221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 2 conditions, with Trigeminal Neuralgia (TN) appearing as the primary indexed condition, and to 4 interventions - of which BIIB074 Treatment A is the first listed.
NCT02951221 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02951221 about?
NCT02951221 is a clinical study titled "New Formulation and Food Effect Study of BIIB074". The primary objectives of the study are to assess the relative bioavailability of the BIIB074 direct compression formulation (DCF) to the BIIB074 roller compaction formulation (RCF) and to determine the effect of a high-fat meal on the pharmacokinetics (PK) of the BIIB074 DCF. The secondary objectiv...
What is the current status of trial NCT02951221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12. Estimated completion is 2017-02.
What conditions does trial NCT02951221 study?
This clinical trial studies the following conditions: Trigeminal Neuralgia (TN), Other Neuropathic Pain.
What interventions are being tested in trial NCT02951221?
The interventions under investigation include: BIIB074 Treatment A (DRUG), BIIB074 Treatment B (DRUG), BIIB074 Treatment C (DRUG), BIIB074 Treatment D (DRUG).
Who is sponsoring clinical trial NCT02951221?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02951221 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02951221's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia